UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5326-5334

2008

Volltextzugriff (PDF)

p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase

PloS one, 2010-05, Vol.5 (5), p.e10486

2010

Volltextzugriff (PDF)

Wild-Type p53 Triggers a Rapid Senescence Program in Human Tumor Cells Lacking Functional p53

Proceedings of the National Academy of Sciences - PNAS, 1997-09, Vol.94 (18), p.9648-9653

1997

Volltextzugriff (PDF)

Clinical Outcomes Associated with Bevacizumab‐Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

The oncologist (Dayton, Ohio), 2009-09, Vol.14 (9), p.862-870

2009

Volltextzugriff (PDF)

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.159-170

2018

Volltextzugriff (PDF)

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States

BMJ open, 2018-07, Vol.8 (7), p.e019955-e019955

2018

Volltextzugriff (PDF)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

Oncotarget, 2017-10, Vol.8 (47), p.81926-81935

2017

Volltextzugriff (PDF)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Blood cancer journal (New York), 2018-09, Vol.8 (10), p.90-4, Article 90

2018

Volltextzugriff (PDF)

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

BMC cancer, 2016-08, Vol.16 (1), p.652-652, Article 652

2016

Volltextzugriff (PDF)

Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

Therapeutics and clinical risk management, 2015-01, Vol.11 (default), p.1355-1360

2015

Volltextzugriff (PDF)

Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage

Cancer research (Chicago, Ill.), 1998-10, Vol.58 (19), p.4439-4444

1998

Volltextzugriff (PDF)

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Blood, 2015-12, Vol.126 (23), p.2870-2870

2015

Volltextzugriff (PDF)

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

Blood, 2016-12, Vol.128 (22), p.4768-4768

2016

Volltextzugriff (PDF)

Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18548-e18548

2016

Volltextzugriff (PDF)

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

Blood, 2016-12, Vol.128 (22), p.3190-3190

2016

Volltextzugriff (PDF)

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7022-7022

2017

Volltextzugriff (PDF)

Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7014-7014

2016

Volltextzugriff (PDF)

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Blood, 2013-11, Vol.122 (21), p.2975-2975

2013

Volltextzugriff (PDF)

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Blood, 2015-12, Vol.126 (23), p.3319-3319

2015

Volltextzugriff (PDF)

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Blood, 2015-12, Vol.126 (23), p.2867-2867

2015

Volltextzugriff (PDF)

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Blood, 2014-12, Vol.124 (21), p.414-414

2014

Volltextzugriff (PDF)

Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS7126-TPS7126

2014

Volltextzugriff (PDF)

Mitochondrial membrane potential in aging cells

Biological signals and receptors, 2001-05, Vol.10 (3-4), p.176-188

2001

Volltextzugriff (PDF)

Reduced Mitochondrial Membrane Potential and Altered Responsiveness of a Mitochondrial Membrane Megachannel in p53-Induced Senescence

Biochemical and biophysical research communications, 1999-07, Vol.261 (1), p.123-130

1999

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(48)
Bücher
(1)

Sprache

Englisch
(49)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase

Wild-Type p53 Triggers a Rapid Senescence Program in Human Tumor Cells Lacking Functional p53

Clinical Outcomes Associated with Bevacizumab‐Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry

Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q)

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry

Mitochondrial membrane potential in aging cells

Reduced Mitochondrial Membrane Potential and Altered Responsiveness of a Mitochondrial Membrane Megachannel in p53-Induced Senescence

Suchergebnisse filtern